Effective tumor cell death by σ-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8975-8983

  Ostenfeld, Marie Stampe ^a   Fehrenbacher, Nicole ^a   Hoyer Hansen, Maria ^a   Thomsen, Christian ^b   Farkas, Thomas ^a   Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYLCARBOXAMIDE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYLCARBOXAMIDE; BUTYLATED HYDROXYANISOLE; CA 074 ME; CALPASTATIN; CASPASE INHIBITOR; CATHEPSIN B; CATHEPSIN B INHIBITOR; ENZYME INHIBITOR; GAMMA TOCOPHEROL; LIGAND; PD 150606; PIPERIDINE DERIVATIVE; PROTEIN BCL 2; PROTEIN P53; R 2525; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE INHIBITOR; SIGMA OPIATE RECEPTOR; SIGMA2 RECEPTOR; SIRAMESINE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL STRAIN 3T3; CELL STRAIN HEK293; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EMBRYO CELL; FEMALE; FIBROBLAST; FIBROSARCOMA; HELA CELL; HUMAN; HUMAN CELL; LYSOSOME MEMBRANE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE SRC; ONCOGENE V HA RAS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CATHEPSINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYTOCHROMES C; FEMALE; FIBROSARCOMA; HUMANS; INDOLES; LIGANDS; LYSOSOMES; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; OXIDATIVE STRESS; RECEPTORS, SIGMA; SPIRO COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 25444483322     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0269     Document Type: Article

References (43)

1. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 2004;174:301-19.
2. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995;278:151-60.
3. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002;62:313-22.
4. Vilner BJ, John CS, Bowen WD. σ-1 and σ-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995;55:408-13.
5. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the σ-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004;64:4875-86.
6. Al-Nabulsi I, Mach RH, Wang LM, et al. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of σ-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 1999;81:925-33.
7. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of σ binding sites. Trends Pharmacol Sci 1992;13:85-6.
8. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of σ1 and σ2 receptors, characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994;268:9-18.
9. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1σ receptor (hσR1). Biochem Biophys Res Commun 1996;229:553-8.
10. Vilner BJ, Bowen WD. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 1993;244:199-201.
11. Post A, Rucker M, Ohl F, et al. Mechanisms underlying the protective potential of α-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002;26:397-407.
12. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998;71:1002-12.
13. Behl C, Rupprecht R, Skutella T, Holsboer F. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport 1995;7:360-4.
14. Vilner BJ, Bowen WD. Modulation of cellular calcium by σ-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000;292:900-11.
15. Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004;64:5029-35.
16. + channel inhibition and p27kip1 accumulation. J Pharmacol Exp Ther 2004;311:1105-14.
17. Crawford KW, Coop A, Bowen WD. σ(2) Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 2002;443:207-9.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
19. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
20. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004;23:2746-56.
21. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004;112:693-700.
22. Everaert H, Flamen P, Franken PR, Verhaeghe W, Bossuyt A. σ-receptor imaging by means of 1123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer. Anticancer Res 1997;17:1577-82.
23. Perregaard J, Moltzen EK, Meier E, Sanchez C. σ ligands with subnanomolar affinity and preference for the σ2 binding site. 1. 3-(ω-aminoalkyl)-1H-indoles. J Med Chem 1995;38:1998-2008.
24. Søby KK, Mikkelsen JD, Meier E, Thomsen C. Lu 28-179 labels a σ(2)-site in rat and human brain. Neuropharmacology 2002;43:95-100.
25. Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs 2001;2:266-70.
26. Jäättelä M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer 1995;60:689-93.
27. Jäättelä M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995;10:2297-305.
28. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004;64:5301-10.
29. Foghsgaard L, Wissing D, Mauch D, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001;153:999-1010.
30. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:89-98.
31. Jänicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
32. Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem J 2001;359:335-43.
33. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004;200:425-35.
34. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
35. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999;18:7719-30.
36. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of α-tocopherol (vitamin E). FEBS Lett 2002;519:8-10,
37. Mukherjee AK, Ghosal SK, Maity CR. Lysosomal membrane stabilization by α-tocopherol against the damaging action of Vipera russelli venom phospholipase A2. Cell Mol Life Sci 1997;53:152-5.
38. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 2003;22:271-86.
39. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A 2005;102:192-7.
40. Jimeno JM. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 2002;13 Suppl 1:S15-9.
41. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
42. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
43. Gebreselassie D, Bowen WD. σ-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol 2004;493:19-28.